The FDA has granted Breakthrough Therapy designation for litifilimab for the treatment of cutaneous lupus erythematosus, a chronic autoimmune skin disease.

The FDA has granted breakthrough therapy designation for litifilimab in patients with cutaneous lupus erythematosus, ...

Our most recent episode of The Expert Series podcast explores the newly released SLE treatment guidelines and how they might affect patient care.

There are a few to keep in mind.

The Lupus Research Alliance applauds the decision by the U.S. Food and Drug Administration (FDA) to grant Breakthrough Therapy designation for litifilimab (BIIB059) in clinical development by Biogen ...

You've changed. And your care plan should too.

Lupus is a type of autoimmune disease. In an autoimmune disease, something goes wrong in the body’s immune system, causing it to harm healthy organs, tissues, and cells. “Auto” means “self” — so if ...

Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous ...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for ...

Today, the Lupus Research Alliance, the world's largest private funder of lupus research, announced the 2025 Global Team ...

Kyleigh MacGregor plans her life five years at a time. MacGregor has lupus, an incurable disease in which her immune system attacks her body’s organs and tissue. It’s been a year since MacGregor, 31, ...

SEN. Bong Go has hailed the approval on third and final reading of Senate Bill (SB) 1513, or the proposed Comprehensive Lupus ...